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Abstract 31 
Introduction: Soluble tumor necrosis factor-like weak inducer of apoptosis 32 
(sTWEAK) is linked to endothelial dysfunction; a key factor in pre-eclamptic 33 
pathogenesis. This study aimed to compare sTWEAK levels during pregnancy to 34 
assess for its prognostic ability. 35 
Materials and Methods: Sixty three high risk pregnant women were followed up from 36 
12 weeks of gestation till term. Serum levels of sTWEAK and platelet derived growth 37 
factor (PlGF), blood pressure, serum glucose, uric acid, urea/creatinine and liver 38 
function tests were measured. Subjects were stratified according to the ACOG criteria 39 
as women who developed PE, or PIH or remained normotensive at term. A negative 40 
control group of normotensive healthy pregnant women (n=17) was also recruited for 41 
comparison.   42 
Results: Baseline sTWEAK levels were lower (4.03±0.37ng/dl) in HR cohort that 43 
developed PE and further reduced at term (1.93±0.23ng/dl) as compared to HR subjects 44 
who remained normotensive and negative control group (30.53±0.79ng/dl; p<0.01). 45 
Likewise PlGF levels were significantly lower (74.22±10.11pg/ml) in HR cohort that 46 
developed PE (p=0.013). At term 39.68% (n=22) HR subjects with low sTWEAK 47 
developed PIH and 34.92% (n=24) developed PE.  In terms of high risk characteristics 48 
observed in the HR group; 73% of the subjects were multiparous, whereas 26.98% 49 
reported to have developed PE in previous pregnancies.   50 
Conclusion: sTWEAK levels at early pregnancy weeks were found to be low in high 51 
risk females who developed PE at follow up versus normotensive pregnant women. 52 
Baseline TWEAK might serve as an independent variable for prediction of pre-53 
eclampsia; however longitudinal studies with larger sample size are required to 54 
ascertain the causal relation.  55 
Key words: Hypertension; Pregnancy; Pre-eclampsia; sTWEAK 56 
57 
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Introduction 58 
Pre-eclampsia, is characterized by sudden onset of hypertension and proteinuria in 59 
women with no preceding hypertensive history. Due to its dormant nature, it possess 60 
great threat to maternal as well as fetal wellbeing (1). Globally 5-14% of all 61 
pregnancies are complicated by PE and in developing countries it’s prevalence is 4-62 
18% (2). PE is a multifactor disorder, starting with placental dysfunction leading to 63 
augmented anti-angiogenic response in mother (3). With the loss of balance between 64 
pro- and antiangiogenic factors, the maternal endothelial function deteriorates (4). It 65 
has also been proposed that normal pregnancy features subservient inflammatory 66 
response in itself, however, in PE this response is augmented. The augmented systemic 67 
response causes dysfunction in maternal endothelium by involving maternal 68 
leukocytes, platelets and also activating pro-inflammatory cytokines (5-7).  69 
For PE, early prediction has always been the primary priority of many clinician and 70 
researchers. Previous maternal history and presence of risk factors alone are not 71 
reliable for the prediction; therefore more profound monitoring is required for prompt 72 
diagnosis and fruitful treatment strategies. Keeping this in view, detection of PE 73 
biomarkers in early pregnancy has always been an interesting field of research (8). 74 
Placental growth factor (PlGF), pregnancy associated plasma protein A (PAPP-A), 75 
Free fetal hemoglobin (HbF), Soluble Endoglin and placental protein 13 (PP-13) are 76 
among some of the commonly studied biomarkers for PE pathology (9, 10) (11). Yet 77 
the predictive value as a single most important, reliable, and effective marker has not 78 
been proven till date (12). Among previously identified predictive serum proangiogenic 79 
biomarker related to pre-eclamptic pathogenesis is placental growth factor (PlGF) (13). 80 
PlGF is a member of vascular endothelial growth factor (VEGF) family and is highly 81 
expressed in placental tissue for healthy placentation (14). The placental angiogenic 82 
factors are responsible for proper placental development through neovascularization, 83 
cellular remolding and maintaining nitric oxide levels. Lack of these factors seem to 84 
play role in defective placentation (15). Serum PlGF levels were found to be reduced in 85 
early weeks of pregnancy by multiple studies (16, 17), thus indicating its role in pre-86 
eclamptic pathogenesis. 87 
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Recently, a new serum marker, soluble tumor necrosis factor like weak inducer of 88 
apoptosis (sTWEAK), has been proposed to be altered in the maternal blood. sTWEAK 89 
is a multipurpose cytokine which is involved in conducting diverse biological events, 90 
like cellular multiplication, growth, migration, angiogenesis, cell differentiation, 91 
apoptosis and inflammation by instigating expression of multiple pro-inflammatory 92 
cytokines. Furthermore, in peculiar it appears to perform critical role in tissue repair 93 
and wound healing (3). TWEAK is universally expressed as Type II trans-membrane 94 
protein of 35-kDA which after cleaving, shed functionally active soluble 18-kDA 95 
processed factor called as  sTWEAK (18). sTWEAK is widely expressed in many 96 
different tissues (19). Overall data suggests that sTWEAK may have physiological as 97 
well as pathological responses in tissues. On one hand it is known to induce 98 
proliferation of endothelial cells in vitro and angiogenesis in vivo and on other hand 99 
triggers the production of pro-inflammatory cytokines (20). Binding of sTWEAK to its 100 
receptor results in activation of any one of the three effector pathways; a) proliferative, 101 
b) inflammatory or c) apoptotic, in which the inflammatory pathway being the most 102 
dominant one. The other 2 pathway activation depends on the cellular integrity. With 103 
intact cellular physiological mechanisms along with absence of inflammatory process, 104 
the effector pathway will be the proliferative pathway, however in the presence of pro-105 
inflammatory cytokines (TNF-α, IFN γ), the predominant pathway is the apoptotic one 106 
(21). In this context, Donohue and group have demonstrated the in vivo stimulatory 107 
effect of sTWEAK on angiogenesis in human endothelial cells (3, 22). 108 
Since pregnancy is the condition comprising of both angiogenesis and mild 109 
inflammation; there might be possibility of sTWEAK’s involvement in these processes 110 
at the time of placentation. Further any alteration in the levels of sTWEAK and PlGF 111 
in the beginning of pregnancy may lead to development of PE. Keeping the literature in 112 
view, we proposed that there might be close relation of pre-eclamptic pathogenesis to 113 
disrupted angiogenic system and endothelial dysfunction caused by low sTWEAK. 114 
Hence, this study aimed to compare sTWEAK levels during pregnancy to assess for its 115 
prognostic ability. 116 
 117 
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Methods:  118 
This prospective study was conducted from January 2017 to March 2018. The study was 119 
approved by the Intuitional Review Board (IRB) of Jinnah Post Graduate Medical Centre 120 
(JPMC) (Ref: NO.F.2-81/GENL-2017-IRB/15107/JPMC) and Aga Khan University (4523-BBS-121 
ERC-16) in collaboration with Taj Medical Complex, Karachi. The minimum sample required 122 
for this study was 60 subjects with a 95% confidence interval and a 4% frequency of outcome 123 
factor in the population (23). A total of n=137 pregnant women were initially enrolled from the 124 
obstetrical clinics of these hospitals; out of these n=80 subjects were successfully followed till 125 
the end of study and were included in this manuscript.  126 
Out of the study cohort; 63 subjects were classified as high risk pregnant women (HR group). 127 
The HR status was based on the presence of any of the criteria: first pregnancy/ family history of 128 
PE/ multiple gestation/ previous history of PE/ maternal age up to 35 years / BMI of >35 kg/m2 129 
and or presence of chronic hypertension. These subjects were followed up from 12 weeks of 130 
gestation till term (observed for development of PE/HTN). Pre-eclampsia diagnoses was based 131 
on the American College of Obstetricians and Gynecologists (ACOG) criteria as follows:- values 132 
of systolic blood pressure 140mm/Hg or higher and diastolic blood pressure 90mm/Hg or higher 133 
after 20 weeks of gestation with or without dipstick proteinuria (0.3gm/l or >1+) were taken as a 134 
reference (24). The remaining (n=17) females who did not show any proteinuria or blood 135 
pressure derangements were labeled as pregnant negative controls. For all study subjects females 136 
with chronic systemic disease (cardiovascular, urogenital, immunological, endocrinological), 137 
renal disease, previous history of complication of pregnancy such as abortion, intra-uterine fetal 138 
demise, antenatal bleeding were excluded from the study.  139 
An informed written consent form was signed by each subject. Their demographic 140 
data, medical and obstetrical history and examination were recorded at the time of 141 
enrolment on a predesigned form. Serum samples were obtained and analyzed for 142 
complete blood count, random blood glucose, uric acid, urea/creatinine and liver 143 
function test. Freshly voided early morning mid-stream urine sample was obtained for 144 
estimation of proteinuria. The serum sTWEAK concentration was determined by using 145 
Human sTWEAK ELISA Kit (Cat. No. H1911 by Glory Science Co, Ltd Belgium) and 146 
PlGF (kit cat #DPG00 by R&D systems USA) according to the provided protocol. In 147 
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high risk and control group, blood samples were collected a) at baseline (12-16weeks) 148 
and b) follow-up (28-36 weeks gestation).  149 
Statistical analysis was conducted by SPSS version 23.0. A descriptive statistical 150 
analysis of continuous variables was performed. Data on continuous variables i.e. 151 
biophysical (age, height, weight, blood pressure etc.) and biochemical (Serum 152 
sTWEAK, PlGF, blood glucose, serum uric acid, serum creatinine, etc.) parameters 153 
were expressed as Mean ± standard deviation (SD) or standard error of mean (SEM) 154 
whereas data on categorical variables were presented as absolute number and 155 
percentages. Statistical comparisons were performed by using student t-test, paired 156 
sample t-test and Mann Whitney-U-test for continuous/quantitative variables, chi-157 
square or Fisher exact test for categorical variables. In all statistical analysis only p-158 
value < 0.05 was taken as significant. 159 
Results  160 
The detailed results of this study are shown in Tables 1-3. Table 1 shows the 161 
demographic distribution of study cohort. Mean age, BMI, weight, hemoglobin levels 162 
and blood glucose parameters were matched for each group therefore no difference was 163 
seen (p>0.05). Alkaline phosphatase levels were slightly raised in HR (243.38±78.36 164 
mg/dl) as compared to control group (167.0±120.22 mg/dl; p=0.039). Serum uric acid 165 
and urea showed no difference among the groups (p>0.05). In terms of high risk 166 
characteristics observed in the HR group; 73% study subjects were multiparous, 167 
whereas 26.98% reported to have developed PE in previous pregnancies.   168 
Table 2 shows the systolic and diastolic blood pressure of study subjects stratified 169 
according to the HR outcome. Baseline blood pressure reading of each subject was 170 
within normal range; whereas subjects who developed PIH (n=24) or PE (n=22) had 171 
significantly higher blood pressure readings than normotensive HR subjects (n=17) and 172 
negative control group (n=17) (p<0.01). The urine dipstick assay for urine protein and 173 
glucose showed 22% of HR subjects with positive proteinuria while 3.2% were 174 
positive for glycosuria varying degrees.   175 
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The assessment of baseline sTWEAK levels revealed a lower value (4.03±0.37ng/dl) in 176 
subjects that developed PE and were further reduced at term (1.93±0.23ng/dl) in 177 
comparison to normotensive HR subjects and negative control group (p<0.001). 178 
Similar trend was observed for baseline and follow up sTWEAK levels of HR subjects 179 
who developed PIH (p<0.001). Likewise, PlGF levels were significantly low in HR 180 
cohort that developed PE (74.22±10.11ng/dl) or PIH (89.38±8.38ng/dl) as compared to 181 
normotensive HR (101.0±12.13ng/dl) and negative controls (109.82±7.83ng/dl) 182 
(p=0.013) (Table 3). The pregnancy outcomes of these HR subjects were as follows: 2 183 
IUGR; 3 IUD’s; 19 LSCS; where the remaining 24 were delivered via simple vaginal 184 
deliveries. 185 
  186 
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Discussion: 187 
Recent advancements in pre-eclamptic management has upgraded the level of safe 188 
pregnancy and to some extent reduced the mortality and morbidity in developed 189 
countries, however in developing countries there is still a need to improve the 190 
pregnancy outcome by early detection of pregnancy complications. In this study, 191 
sTWEAK has emerged as a promising contemporary biomarker for early pre-eclamptic 192 
prediction in women having risk factors such as multiple pregnancies, previous history 193 
of PE and age of up to 35 year. The study reports that a considerable number of 194 
pregnant subjects with remarkably lower sTWEAK levels at baseline and follow up 195 
developed either pre-eclampsia or pregnancy induced hypertension near term. This 196 
finding reinforces the assumption that low sTWEAK is related with the progression or 197 
disease severity (21). Therefore, it is plausible that this finding may give a novel 198 
insight into the ability of sTWEAK to identify high risk subjects during early 199 
pregnancy weeks for the first time that may develop PE later. This finding is in 200 
consensus with the only available published study which found decreased serum 201 
sTWEAK concentration in pre-eclamptic women as compared to controls (p-value  202 
0.04) (3). However, there is a slight difference in reported concentrations that may be 203 
attributed to a different population, different time of sample collection and difference 204 
assay protocol. Moreover, in this study sTWEAK levels were slightly lower (but not 205 
below 9ng/dl) in normotensive HR subjects in comparison to pregnant controls, which 206 
could be due to the presence of risk factors influencing the general condition of the 207 
patients. In addition, these subjects had a normal PlGF level that might have 208 
compensated for the changes in pregnancy.  209 
Currently, no research data is available regarding the role of sTWEAK in pre-eclamptic 210 
pathogenesis. However, several previous studies have identified sTWEAK as a potent 211 
inducer of angiogenesis, acting as a mitogenic factor for human endothelial cells (25). 212 
It is also found to be linked with endothelial dysfunction in non-dialysis chronic kidney 213 
disease, diabetic and renal transplant patients (26). Decreased sTWEAK concentrations 214 
were also detected in conditions like atherosclerosis, coronary artery disease and 215 
peripheral arterial disease (27). Another group linked lower sTWEAK to inflammatory 216 
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changes in gestational diabetes (GDM) and insulin resistance (28); however in this 217 
study only 2 cases of GDM were observed.  218 
The current study also reports a reduced maternal serum PlGF level along with reduced 219 
sTWEAK levels in early pregnancy indicating its link to pre-eclamptic pathogenesis. 220 
Maternal PlGF involvement in proper placentation through effective angiogenesis has 221 
been proved previously (29). PlGF works as a mitogenic factor for endothelial cells 222 
and its levels are high throughout the pregnancy (14), therefore, the reduced levels of 223 
PlGF may predict pre-eclampsia (30). However, studies have proposed that PlGF alone 224 
has a limited predictive capacity (31).  The predictive value of most of the biomarkers 225 
working as a single entity is not satisfactory unless a combination of markers are used 226 
(9). Since this study suggests sTWEAK ability to predict PE as an independent marker, 227 
introducing the new combination of sTWEAK and PlGF may enhance the screening 228 
capabilities for the disease in early weeks of pregnancy. 229 
The connection of sTWEAK with the pre-elcamptic pathogenesis can be explained by 230 
its behavior as an inflammatory cytokine. Since pregnancy is considered as a low grade 231 
inflammatory condition (32); sTWEAK physiological or pathological nature, may have 232 
some contribution in pre-eclamptic pathogenesis, owing to the fact of exaggerated 233 
maternal inflammatory response in pre-eclamptic pregnancy (33). Published data also 234 
suggest the role of sTWEAK in neovascularization (25), there might be a possibility 235 
that deficiency of sTWEAK in the blood is responsible for defective angiogenesis in 236 
placenta leading to PE as seen in this study.  237 
In Pakistan, the overall estimated incidence of intra uterine deaths is around 5.22% (34) 238 
which is linked to cases of antepartum hemorrhage, hypertensive disorders of 239 
pregnancy (preeclampsia and eclampsia), mismanagement of labor and diabetes etc. In 240 
this study, the number of IUD’s reported was 3 (4.76%) and IUGR was 2 (3.17%) in 241 
the PE/PIH group, which is comparable to the available data (35, 36). 242 
This study was however limited on commenting on the prediction of early onset and 243 
late onset PE as the number of patients in this study design was limited. Additionally, it 244 
is uncertain whether sTWEAK is superior in predicting PE alone or in coalition with 245 
other angiogenic factors such as PlGF. This ensues for the requirement of more 246 
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prospective studies in assessing the role of sTWEAK alone and comparing its 247 
prognostic performance when combined with other biomarkers. Despite the limitations, 248 
this is perhaps the first prospective study on the role of sTWEAK in diagnosing PE and 249 
these findings may open ways for future researchers in assessing the molecular events 250 
that lead to the disease pathogenesis.   251 
Conclusion: 252 
sTWEAK levels at early pregnancy weeks were found to be low in high risk females 253 
who developed pre-eclampsia at follow up versus normotensive pregnant women. 254 
Baseline TWEAK might serve as an independent variable for prediction of pre-255 
eclampsia; however longitudinal studies with larger sample size are required to 256 
ascertain the causal relation. 257 
Conflicts of interest: none declared. 258 
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Figure 1:  Schematic Research Methodology and Outcome of High risk Subjects 290 
Potentially Eligible Subjects 
n=137 
 Ethical permission by concerned Institutes 
Informed Written Consent 
Included (n=80): 
 High risk pregnant women (HR) 
 Healthy pregnant women as controls 
 Between 13-20 weeks of gestation 
Excluded (n=11): 
 Chronic systemic diseases (Immunological, 
endocrinological and renal disease) n=06 
 Previous history of complication of pregnancy 
(abortion, antenatal bleeding) n=05 
Dropped out (n=46) 
 Failed to consent or lost to follow up 
High Risk Group 
High risk pregnant women 
n=63 
Control Group 
Healthy pregnant women 
n=17 
Pre-Eclampsia n=22 
PIH n=24 
Normotensive n=15   
Gestational Diabetes n=2   
Low sTWEAK at baseline & follow up 
Baseline (12-16weeks gestation) and follow-up (28-36 weeks gestation) 
 Blood and Urine Collection for biomarker testing  
  Blood Pressure Measurements  
 Diagnosis of pre-eclampsia was made on recommendations of ACOG 
criteria 2013 
 
Normal sTWEAK at baseline & follow up 
Outcome of High Risk group 
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Table 1: Baseline Data of the study Cohort 291 
 292 
  293 
 
High risk group 
n=63 
Negative Control 
n=17 
P value 
Age (year) 27.05± 5.89 30.65 ± 9.40 0.474 
Weight (kg) 68.65±19.34 62.71±14.22 0.488 
Body mass index (kg/m2) 27.01±7.02 24.14±5.30 0.248 
Hemoglobin (g %) 11.2±1.20 11.35±1.01 0.334 
Random Blood Glucose  (mg/dl) 96.24±23.66 98.45±10.27 0.840 
SGPT (U/L) 21.73±10.7 10.00±1.22 0.040 
Alkaline Phosphatase (U/L) 243.3±78.36 167.0±120.22 0.039 
Total Bilirubin (mg/dl) 0.571±0.21 0.30±0.11 0.145 
Direct Bilirubin (mg/dl) 0.13±0.03 0.10±0.02 0.601 
Serum Uric Acid (mg/dl) 3.91±1.09 3.50±1.00 0.540 
Serum Urea (mg/dl) 16.45±5.76 12.00±2.45 0.260 
Serum Creatinine (mg/dl) 0.60±0.12 0.80±0.11 0.250 
Parity  
Primi 17 (26.98) 14 (82.23) 
<0.01 
Multi 46 (73.01) 2 (11.76) 
Previous History of PE 17 (26.98) -- <0.001 
No of fetus 
Singleton 60 (95.23) 17 (100) 
0.621 
Multiple 3 (4.76) -- 
Values expressed as Mean ± SEM and absolute values and percentages in parenthesis. Comparison between groups was made by 
Man Whitney U test, Chi square statistics or Fischer exact test.   Statistically significant as compared to normotensives  p<0.05 
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 294 
Table 2: Serial Blood Pressure Measurements, Proteinuria and Glycosuria in HR & 295 
Control Groups  296 
     297 
Blood Pressure 
In Different 
Gestational weeks 
High Risk Group (n=63) Negative 
Control 
 (n=17) 
p 
value Developed 
PE  (n=22) 
Developed 
PIH (n=24) 
Normotensive 
(n=17) 
Systolic Baseline (mmHg) at 
12 weeks 
120.00 ±17.45 118.10±15.84 114.70 ± 7.98 110.59±13.44 0.124 
Diastolic Baseline (mmHg) at 
12 weeks 
78.64 ± 14.57 75.48±13.98 74.38 ± 8.92 72.35±9.701 0.059 
Systolic Follow up at (mmHg) 
28 weeks 
159.50 ± 17.00 121.00±4.55 112.35 ± 9.70 109.09±10.41 0.007 
Diastolic Follow up at (mmHg) 
28 weeks 
93.81 ± 16.57 89.25 ± 11.20 75.29 ± 7.99 82.05±8.80 0.412 
Systolic Follow up at (mmHg) 
32 weeks 
133.64 ± 16.84 
127.62 ± 
13.43 
111.76 ± 9.51 108.22±5.89 0.009 
Diastolic Follow up at (mmHg) 
32 weeks 
85.50 ± 6.048 85.59 ± 9.735 79.62 ± 3.54 79.55±8.45 0.052 
Urine Dipstick Analysis for Protein and Glucose 
 
High Risk Group  
(n=63) 
Negative Control 
 (n=17) 
Urine Protein 
0 49 (77.9) 15 (88.23) 
1+ 5 (7.9) 2 (11.76) 
2+ 2 (3.2) -- 
3+ 7 (11.1) -- 
Urine Glucose 
0 61 (96.8) 17 (100) 
1 2 (3.2) -- 
Values expressed as Mean ± SEM or as absolute values and percentages in parenthesis. Comparison between groups was made 
by Man Whitney U test. Statistically significant as compared to normotensive and control p<0.05. 
          298 
 299 
                     300 
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Table 3:  sTWEAK and PlGF Levels in subjects stratified based on HR group outcomes 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
  312 
Biomarkers 
High Risk Group (n=63) Negative 
Control 
(n=17) 
p-value Developed 
PE  (n=22) 
Developed 
PIH (n=24) 
Normotensive 
(n=17) 
sTWEAK Baseline (ng/dl) 4.03 ± 0.37 5.80 ± 0.56 13.29 ± 0.70 15.10± 0.64 <0.001 
sTWEAK Follow up (ng/dl) 1.93 ± 0.23 8.35 ± 0.78 10.13 ± 1.10 30.53± 0.79 <0.001 
PlGF  (pg/ml) 74.22± 10.11 89.38 ± 8.38 101.0 ± 12.13 109.82 ± 7.83 0.013 
Values expressed as Mean ± SEM. Comparison between groups was made by T Test, Man Whitney U test. 
  Statistically significant as compared to normotensives  p<0.05 
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